RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0040-1712106
Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival
Funding Stiftelsen Acta Oto-Laryngologica; The ALF project funding for clinically oriented medical research projects; The Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland.![](https://www.thieme-connect.de/media/10.1055-s-00025477/202103/lookinside/thumbnails/10-1055-s-0040-1712106_190061-1.jpg)
Abstract
Introduction Head and neck cancer of unknown primary (HNCUP) is a rare condition whose prognostic factors that are significant for survival vary between studies. No randomized treatment study has been performed thus far, and the optimal treatment is not established.
Objective The present study aimed to explore various prognostic factors and compare the two main treatments for HNCUP: neck dissection and (chemo) radiation vs primary (chemo) radiation.
Methods A national multicenter study was performed with data from the Swedish Head and Neck Cancer Register (SweHNCR) and from the patients' medical records from 2008 to 2012.
Results Two-hundred and sixty HNCUP patients were included. The tumors were HPV-positive in 80%. The overall 5-year survival rate of patients treated with curative intent was 71%. Age (p < 0.001), performance status (p= 0.036), and N stage (p= 0.046) were significant factors for overall survival according to the multivariable analysis. Treatment with neck dissection and (chemo) radiation (122 patients) gave an overall 5-year survival of 73%, and treatment with primary (chemo) radiation (87 patients) gave an overall 5-year survival of 71%, with no significant difference in overall or disease-free survival between the 2 groups.
Conclusions Age, performance status, and N stage were significant prognostic factors. Treatment with neck dissection and (chemo) radiation and primary (chemo) radiation gave similar survival outcomes. A randomized treatment study that includes quality of life is needed to establish the optimal treatment.
Keywords
head and neck cancer - cancer of unknown primary - prognostic factors - human papillomavirus - treatmentPublikationsverlauf
Eingereicht: 10. November 2019
Angenommen: 25. März 2020
Artikel online veröffentlicht:
30. September 2020
© 2020. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Swedish Head and Neck Cancer Register (SweHNCR). http://www.cancercentrum.se/samverkan/cancerdiagnoser/huvud-och-hals/kvalitetsregister
- 2 Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55 (02) 121-129
- 3 Huang CC, Tseng FY, Yeh TH. et al. Prognostic factors of unknown primary head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2008; 139 (03) 429-435
- 4 Beldì D, Jereczek-Fossa BA, D'Onofrio A. et al. Role of radiotherapy in the treatment of cervical lymph node metastases from an unknown primary site: retrospective analysis of 113 patients. Int J Radiat Oncol Biol Phys 2007; 69 (04) 1051-1058
- 5 Boscolo-Rizzo P, Gava A, Da Mosto MC. Carcinoma metastatic to cervical lymph nodes from an occult primary tumor: the outcome after combined-modality therapy. Ann Surg Oncol 2007; 14 (05) 1575-1582
- 6 Axelsson L, Nyman J, Haugen-Cange H. et al. Prognostic factors for head and neck cancer of unknown primary including the impact of human papilloma virus infection. J Otolaryngol Head Neck Surg 2017; 46 (01) 45
- 7 Zhou MJ, van Zante A, Lazar AA. et al. Squamous cell carcinoma of unknown primary of the head and neck: Favorable prognostic factors comparable to those in oropharyngeal cancer. Head Neck 2018; 40 (05) 904-916
- 8 Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head-and-neck mucosal site treated with radiation therapy alone or in combination with neck dissection. Int J Radiat Oncol Biol Phys 2001; 50 (01) 55-63
- 9 Iganej S, Kagan R, Anderson P. et al. Metastatic squamous cell carcinoma of the neck from an unknown primary: management options and patterns of relapse. Head Neck 2002; 24 (03) 236-246
- 10 Strojan P, Anicin A. Combined surgery and postoperative radiotherapy for cervical lymph node metastases from an unknown primary tumour. Radiother Oncol 1998; 49 (01) 33-40
- 11 Sivars L, Näsman A, Tertipis N. et al. Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome. Cancer Med 2014; 3 (02) 376-384
- 12 Keller LM, Galloway TJ, Holdbrook T. et al. p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head Neck 2014; 36 (12) 1677-1684
- 13 Aslani M, Sultanem K, Voung T, Hier M, Niazi T, Shenouda G. Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site: Is there a need for neck dissection?. Head Neck 2007; 29 (06) 585-590
- 14 Hauswald H, Lindel K, Rochet N, Debus J, Harms W. Surgery with complete resection improves survival in radiooncologically treated patients with cervical lymph node metastases from cancer of unknown primary. Strahlenther Onkol 2008; 184 (03) 150-156
- 15 Bataini JP, Rodriguez J, Jaulerry C, Brugere J, Ghossein NA. Treatment of metastatic neck nodes secondary to an occult epidermoid carcinoma of the head and neck. Laryngoscope 1987; 97 (09) 1080-1084
- 16 Coster JR, Foote RL, Olsen KD, Jack SM, Schaid DJ, DeSanto LW. Cervical nodal metastasis of squamous cell carcinoma of unknown origin: indications for withholding radiation therapy. Int J Radiat Oncol Biol Phys 1992; 23 (04) 743-749
- 17 Strojan P, Ferlito A, Langendijk JA. et al. Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck 2013; 35 (02) 286-293
- 18 Eskander A, Ghanem T, Agrawal A. ; Education Committee of American Head and Neck Society (AHNS). AHNS Series: Do you know your guidelines? Guideline recommendations for head and neck cancer of unknown primary site. Head Neck 2018; 40 (03) 614-621
- 19 Farnebo L, Laurell G, Mäkitie A. A Nordic survey on the management of head and neck CUP. Acta Otolaryngol 2016; 136 (11) 1159-1163
- 20 Wallace A, Richards GM, Harari PM. et al. Head and neck squamous cell carcinoma from an unknown primary site. Am J Otolaryngol 2011; 32 (04) 286-290
- 21 Frank SJ, Rosenthal DI, Petsuksiri J. et al. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010; 78 (04) 1005-1010
- 22 Strojan P, Ferlito A, Medina JE. et al. Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck 2013; 35 (01) 123-132
- 23 Swedish national care program for head and neck cancer. https://www.cancercentrum.se/samverkan/cancerdiagnoser/huvud-och-hals/vardprogram/
- 24 Pignon JP, le Maître A, Maillard E, Bourhis J. ; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92 (01) 4-14
- 25 Cuzick J. A method for analysing case-control studies with ordinal exposure variables. Biometrics 1985; 41 (03) 609-621
- 26 KA Stepniewska DA. snp4: Non-parametric test for trend across ordered groups. Stata Technical Bulletin,1992Reprints, vol 2. 169 College Station, TX: Stata Press;
- 27 Reference: StataCorp. Stata: Release 15. Statistical Software. College Station, TX: StataCorp LLC; 2017
- 28 Fakhrian K, Thamm R, Knapp S. et al. Radio(chemo)therapy in the management of squamous cell carcinoma of cervical lymph nodes from an unknown primary site. A retrospective analysis. Strahlenther Onkol 2012; 188 (01) 56-61
- 29 Ligey A, Gentil J, Créhange G. et al. Impact of target volumes and radiation technique on loco-regional control and survival for patients with unilateral cervical lymph node metastases from an unknown primary. Radiother Oncol 2009; 93 (03) 483-487
- 30 Fernández JA, Suárez C, Martínez JA, Llorente JL, Rodrigo JP, Alvarez JC. Metastatic squamous cell carcinoma in cervical lymph nodes from an unknown primary tumour: prognostic factors. Clin Otolaryngol Allied Sci 1998; 23 (02) 158-163
- 31 Klem ML, Mechalakos JG, Wolden SL. et al. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys 2008; 70 (04) 1100-1107
- 32 Motz K, Qualliotine JR, Rettig E, Richmon JD, Eisele DW, Fakhry C. Changes in Unknown Primary Squamous Cell Carcinoma of the Head and Neck at Initial Presentation in the Era of Human Papillomavirus. JAMA Otolaryngol Head Neck Surg 2016; 142 (03) 223-228
- 33 Balaker AE, Abemayor E, Elashoff D, St John MA. Cancer of unknown primary: does treatment modality make a difference?. Laryngoscope 2012; 122 (06) 1279-1282